Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001 Mar;24(3):199-203.
doi: 10.1007/BF03343844.

Clinical application of 5alpha-reductase inhibitors

Affiliations
Review

Clinical application of 5alpha-reductase inhibitors

A Cilotti et al. J Endocrinol Invest. 2001 Mar.

Abstract

The inhibitors of 5alpha-reductase isoenzymes (1 and 2) can be schematically divided in three groups according they substrate specificity: a) pure or preferential inhibitor of 5alpha-reductase 1; b) pure or preferential inhibitor of 5alpha-reductase 2; c) dual inhibitors. Despite the fact that several steroidal and non-steroidal inhibitors have been synthesized and experimented in pharmacological models, only finasteride has been extensively used for clinical purposes. The largest application of finasteride in man has been human benign prostative hyperplasia (BPH). In addition, finasteride has been recently used for treatment of male baldness with a 50% of objective response. In women, finasteride has been used in some control trials for treatment of hirsutism with an objective favorable response. In conclusion, finasteride appears be useful for BPH, baldness and hirsutism (with caution) treatment. On the basis of experimental observations on distribution of 1 and 2 isoenzymes in human skin, scalp and prostate, the dual inhibitors should be more indicated for treatment of BPH and baldness. Similarly, the dual inhibitors seem indicated in attempting to prevent prostatic cancer. The pure 5alpha-reductase 1 inhibitors seem the ideal drugs for treatment of acne and hirsutism.

PubMed Disclaimer

References

    1. J Clin Endocrinol Metab. 1990 Dec;71(6):1552-5 - PubMed
    1. J Clin Endocrinol Metab. 2000 Jul;85(7):2576-83 - PubMed
    1. J Med Chem. 1993 Feb 5;36(3):421-3 - PubMed
    1. N Engl J Med. 1992 Oct 22;327(17):1216-9 - PubMed
    1. Bioorg Med Chem Lett. 1998 Oct 20;8(20):2871-6 - PubMed

LinkOut - more resources